Form 4: Chimerix CEO Michael Sherman Disposes of Shares and Options Following Merger with Jazz Pharmaceuticals

Following the merger of Chimerix with Jazz Pharmaceuticals, CEO Michael Sherman reports the disposal of common stock and cancellation of stock options.

Summary

• Michael A. Sherman, CEO of Chimerix, filed a Form 4 detailing changes in beneficial ownership following the merger with Jazz Pharmaceuticals.
• The merger, executed on April 21, 2025, involved Jazz Pharmaceuticals acquiring Chimerix through a tender offer and subsequent merger.
• Sherman disposed of 87,000 shares of common stock held in a trust, 102,995 shares held by Sherman Investors LLC, and 233,413 directly held shares, all at a price of $8.55 per share.
• He also reported the cancellation of several employee stock option grants, including options to purchase 1,150,000 shares at $2.09, 632,500 shares at $2.08, 700,000 shares at $9.28, 875,000 shares at $5.62, 557,050 shares at $1.97, and 60,000 shares at $0.89.
• In-the-money options were converted into the right to receive a cash payment equal to the difference between the offer price ($8.55) and the exercise price, multiplied by the number of shares subject to the option.
• Options with an exercise price greater than the offer price were cancelled with no consideration.

Sentiment

Score: 7

Explanation: The document is a standard regulatory filing related to a merger. While it signifies the end of Chimerix as an independent entity, the merger provided a defined cash value to shareholders and option holders, leading to a neutral to slightly positive sentiment.

Positives

• The merger provided a cash payout to shareholders at $8.55 per share.
• In-the-money stock options were converted to cash, providing value to option holders.

Negatives

• Stock options that were not 'in the money' were cancelled with no compensation.
• Chimerix ceased to exist as an independent entity.

Future Outlook

The document does not contain any specific forward-looking statements beyond the completion of the merger.

Management Comments

• The foregoing descriptions in the footnotes to this Form 4 are qualified in their entirety by reference to the terms of the Merger Agreement.
• In the event of any conflict between the descriptions above and the terms set forth in the Merger Agreement, the terms set forth in the Merger Agreement shall control.

Industry Context

This announcement reflects a trend of pharmaceutical companies acquiring smaller firms to expand their product portfolios and pipelines. Jazz Pharmaceuticals' acquisition of Chimerix likely aims to leverage Chimerix's assets and expertise in a specific therapeutic area.

Comparison to Industry Standards

• Merger and acquisition (M&A) activity is common in the pharmaceutical industry, with companies like Pfizer, Novartis, and Roche frequently acquiring smaller biotech firms.
• The valuation of Chimerix at $8.55 per share would be assessed against comparable transactions in the biotech sector, considering factors like pipeline stage, market potential, and existing revenue streams.
• The treatment of stock options in M&A deals is standard, with in-the-money options typically cashed out and out-of-the-money options often cancelled.

Stakeholder Impact

• Shareholders received $8.55 per share in cash.
• Employees may experience changes as Chimerix integrates into Jazz Pharmaceuticals.
• Option holders received cash for in-the-money options or had their options cancelled.

Key Dates

Keywords

Merger, Chimerix, Jazz Pharmaceuticals, Form 4, Beneficial Ownership, Stock Options, Shares, CEO, Michael Sherman